The Federal Trade Commission (FTC) revealed that it provided testimony before the US Senate Subcommittee on Antitrust, Competition Policy and Consumer Rights on Tuesday, September 17.
During his testimony, FTC Chairman Joseph J. Simons revealed the agency’s recent successes in preventing anticompetitive mergers and conduct, as well as its significant policy initiatives, advocacy work, and engagement with antitrust enforcement agencies in other countries.
Last year, the agency worked to protect consumers in 22 merger cases in a variety of industries, including obtaining preliminary injunctions in two federal court merger cases. And in two other potential mergers, the parties abandoned their plans after the FTC voted to start litigation.
Other successes include the agency’s unanimous vote in March that Impax Laboratories and Endo Pharmaceuticals had entered into a reverse payment arrangement that delayed entry of generic competition for Opana ER, an extended release opioid for pain relief.
The FTC also sued to stop Evonik Industries AG’s proposed acquisition of PeroxyChem Holding company because it believed the merger would stifle competition in the Pacific Northwest and the southern and central United States for the production and sale of hydrogen peroxide.
The FTC also filed an administrative complaint to block the merger of title insurance providers Fidelity National Financial and Stewart Information Services, leading the companies to cancel the transaction.
Simons also noted during his testimony that the FTC is working to protect competition in technology markets. The agency recently voted to sue Surescripts, alleging that the company engaged in exclusive dealing and other forms of exclusionary behavior to reduce competition and preserve its monopoly.
In addition, the FTC’s Bureau of Competition recently established a Technology Task Force to consolidate and coordinate agency work in this sector.
But just last week, Rohit Chopra, a commissioner with the FTC, said fining Big Tech companies won’t have any real effect on changing the way they run, and more may need to be done.
“We’re not going to solve some of these problems just by small-time fines that aren’t going to change the underlying business model of these firms,” he said. “We actually have to take a hard look at whether these behemoths are killing off innovation and competition.”
Full Content: PYMNTS
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI